tatin therapy, especially intensive doses, is beneficial in atherosclerotic coronary disease. 1-3 Volumetric intravascular ultrasound (IVUS) has been used in statin trials 4,5 to evaluate plaque regression. 6, 7 Intensive statin therapies used in the REVERSAL and ASTEROID Trial appeared to achieve better regression outcomes. 8, 9 Recent clinical evidence supports that stable fibrous plaque is likely to be responsible for stable ischemia, while unstable thin-cap fibroatheroma might be responsible for acute coronary syndrome (ACS). 10 While gray-scale IVUS is insufficient, virtual histology (VH) can characterize plaque composition into 4 virtual components corresponding to histopathology, allowing the in vivo assessment of plaque composition, plaque stability, and responses to treatment to become possible. 11, 12 We believed not only the plaque volume but also the plaque composition can be modified by statin therapy, and we hypothesized that such modifications could be statin-dose dependent.
Methods

Study Design
This was a prospective, randomized, double-blinded study, first Varying Statin Doses on VH-IVUS Composition of its kind in design, utilizing VH-IVUS to evaluate the effects of 2 different doses of atorvastatin on plaque composition, in statin-naive patients requiring percutaneous coronary intervention (PCI) without a previous history of myocardial infarction (MI). The effects on plaque volume and clinical outcomes were also monitored.
These statin-naive patients should definitely be receiving statin treatment after PCI; therefore, for ethical reasons, a placebo control arm was not included, and 2 arms of standard clinical doses of atorvastatin, 10 mg (low dose) and 40 mg (moderate dose), were used.
The whole study is summarized in the CONSORT Flow Chart (Figure 1) . Inclusion criteria required all patients to be statin-naive, free from unstable angina >8 weeks before intervention or ACS, and with angiographic critical coronary stenosis requiring PCI. Exclusion criteria included any history of previous statin treatment, ongoing ACS or being in cardiogenic shock, being a surgical bypass candidate, having chronic total occlusion, and very tortuous or calcified arteries precluding safe IVUS examination. The primary end-point was the VH-IVUS findings at the 6-month IVUS follow up. All major adverse cardiac events (MACE), defined as cardiac death, MI or repeated revascularization at 6 months, were also documented. The study protocol was approved by the University of Hong Kong Ethics Committee (IRB No. 07-266); written informed consent was obtained in all patients.
During the index PCI procedure, baseline IVUS data were obtained from the entire length of the studied vessels with reproducible landmarks (stent-edges, side-branches or big chunks of calcium) distally and proximally, at a pull-back rate of 0.5 mm/s using the R-100 pullback device, the EagleEye 20 MHz phased-array IVUS catheter, and the Volcano In-Vision Gold 3 console (Volcano Corp, Rancho Cordova, CA, USA), before and/or after the stenting procedure, as appropriate. All culprit and non-culprit lesions (definitions below) were identified, labeled and fully documented (refer to Figure 2 for details). Such lesion location and identity information would serve as the references at the 6-month VH-IVUS restudy, as well as during the matched analysis of the VH-IVUS segments at the end of the study. PCI would be performed to all ischemia culprit lesions (angiographically ≥70% stenosis by QCA and/or IVUS lumen cross sectional area <4 mm 2 ). After PCI, all patients were randomized by computer to receive either atorvastatin 10 mg or 40 mg daily for 6 months; all drugs had an identical external package for blinding purposes. Follow-up visits were scheduled monthly until the 6-month restudy. Any MACE outcomes were recorded without unblinding the statin dosage. Both baseline and 6-month IVUS pullbacks were sent for core laboratory analysis in a blinded fashion.
VH-IVUS Lesion Identification and Core Laboratory Analyses
The "worst" 10-mm segment approach used in previous IVUS studies was not used in this study. Rather, a more radical approach was adopted to take in all non-culprit VH-IVUS lesions in all 3 vessels. A non-culprit lesion was defined as any diseased but non-critical lesion not requiring PCI, having lesion margins defined by a percentage plaque area >20% by IVUS, and separated by >10 mm in the distance from the PCI culprit lesion and the stent edge (refer to Figure 2 for details). Total Figure 1 . CONSORT Flow Chart of 40 statin-naive patients enrolled and outcomes at 6 months. Angio or IVUS stenosis represents an angiographic diameter stenosis of ≥70% or IVUS stenosis with a lumen cross sectional area <4 mm 2 . ACS, acute coronary syndrome; TLR, target lesion revascularization; TVR, target vessel revascularization; VH-IVUS, virtual histology intravascular ultrasound. LEE SWL et al.
plaque volume (mm 3 ) was defined as the external elastic membrane (EEM) volume minus the vessel lumen volume. Percentage plaque volume (%) was defined as the percentage of total plaque volume over the total EEM volume. In vivo tissue characterization by VH-IVUS was represented by 4 components, namely fibrous, fibro-fatty, dense calcium and necrotic core component, and assigned a color code of green, yellow, white and red, respectively (Figure 3) . These 4 VH-IVUS components were expressed both in absolute VH-IVUS volume (mm 3 ) and in relative percentage VH component (%) by using an automated program. All VH-IVUS pullbacks were analyzed by a core laboratory (Intravascular Ultrasound Core Laboratory, the Krakow Cardiovascular Research Institute, Poland) which was blinded from all clinical information (refer to Appendix for details). At the end of the study, all data were then unblinded, enabling statistical calculations of the changes from baseline to 6 months, and a comparison of differences between the 2 arms.
Statistical Analyses
Continuous variables are expressed as mean ± SD. Categorical values are presented as counts or percentages and compared by using a chi-square test. Within-group differences were compared by using a 2-tailed paired t-test (or Wilcoxon matched pairs test for variables not normally distributed) and betweengroup differences by an independent t-test (or Mann-Whitney U-test for variables not normally distributed). Statistical adjustments were made for all baseline differences in total plaque volume and fibrous volume stemming from the random variation between the 2 groups in this small sample (the unblinding process was carried out only at the end of the study); statistical inference were made using the linear mixed effect model in which the covariance structures of the data were adjusted for fixed and random effects. A 2-sided P-value of ≤0.05 is considered statistically significant. All statistical analyses were performed using SPSS, (version 16.0, SPSS Inc, Chicago, IL, USA).
Results
From Jan 2008 to May 2009, 40 consecutive patients were randomized (Figure 1) . On day 126, 1 patient in the 10 mg group developed ACS (a plaque rupture adjacent to a stented segment) that required an urgent target vessel revascularization (TVR) and therefore this patient was excluded from the further VH-IVUS restudy; thus only 19 vs. 20 patients completed the VH-IVUS follow-up in the 2 arms.
PCI Procedures and Clinical Outcomes
Patients consented to participate in this study had quite advanced disease as reflected by the large number of lesions treated by PCI, number of stents used, and the number of nonculprit lesions identified for VH-IVUS analysis ( Table 1) . The baseline clinical characteristics and lipid profiles were similar among the 2 groups. All patients had a successful PCI procedure and approximately 80% of stents used were drug-eluting stents. The overall MACE rate in this cohort with advanced disease was 15% (6 of 40). However, after unblinding at the end of the study, apart from the 1 patient who developed ACS on day 126, another patient in the 10 mg group had progression (d) and (e), were identified as potential non-culprit lesions to be recruited for VH-IVUS analysis. Lesion (d) represents a typical VH-IVUS lesion with lesion borders defined by percentage plaque area >20% by IVUS. Lesion (e) has a separating distance >10 mm from the PCI culprit lesion (or stent edge) on the LAD and is qualified for VH-IVUS analysis. Lesion (b) is <10 mm and therefore has to be excluded from VH-IVUS analysis. This angiographic information and labeling were fully documented and made available at the 6 months IVUS restudy, as well as during lesion matching at the final VH-IVUS analysis at the end of the study. PCI, percuataneous coronary intervention; VH-IVUS, virtual histology intravasculare ultrasound. Varying Statin Doses on VH-IVUS Composition of a non-culprit lesion and 4 more had angiographic in-stent restenosis; all patients had percutaneous revascularization during the 6-month angiographic restudy, amounting to a cumulative hierarchical MACE in 6 patients, as compared to zero patient in the 40 mg group, P=0.020 ( Table 1) .
Volumetric Gray-Scale IVUS and Virtual Histology Findings
A total of 54 vs. 57 non-culprit lesions were qualified for VH-IVUS analysis in the 2 arms ( Table 2 ). In the regions of interest (non-culprit lesions), the minimal luminal diameter was 2.89±0.52 mm and the percentage diameter stenosis was 26.1± 37.4%. Incidentally, due to the random assignment by com- 3 , P=0.044, respectively). However, the "percentage plaque volume" and all of the 4 "relative % VH volumes" were absolutely similar between the 2 groups ( Table 2) ; statistical adjustments were made (refer to the previous section) and such baseline differences would pose minimal impact on the study results, which only showed significant differences in the "percentage plaque volume" and the "relative % necrotic core component", both of which were identical at baseline between the 2 groups. Extensive VH-IVUS changes were observed in all these statin-naive patients treated with atorvastatin for 6 months, irrespective of the dose used. These are shown numerically in Table 3 and graphically in the pie charts in Figure 3 . In all 111 VH-IVUS non-culprit lesions that qualified for analysis, the overall absolute plaque volume was reduced by 5.10± 14.93 mm 3 or 4.28%, P<0.001, mostly due to the reduction in fibrous component, which comprised >60% of the total plaque volume (refer to green area in the pie charts in Figure 3 ). There was a 10.54% reduction in absolute fibrous volume (-4.87±10.75 mm 3 A majority of the changes were statistically significant.
Comparing the 2 arms, the within-group changes and between-group differences are shown numerically in Table 3 and graphically in the bar charts in Figure 3 . The bar chart on the left shows the changes in absolute volumes (in mm 3 ). In the low-dose (10 mg) group, a significant reduction of absolute fibrous and fibro-fatty volume, and significant increase in absolute dense calcium and necrotic core volume were recorded. In the moderate-dose (40 mg) group, more reduction in the fibrous volume, no change in the fibro-fatty volume, less increase in dense calcium, and actual reduction in necrotic core volume were recorded. However, no statistically significant between-group differences were recorded in this small sample. The bar chart on the right shows the changes in relative percentages. Both groups showed a within-group reduction in relative percentage fibrous, and increase in dense calcium and necrotic core component, mostly reaching statistical significance. In the between-group comparison, for the 40 mg dose of atorvastatin, more "limitation of necrotic core expansion" was observed in both absolute volume (-4.88% vs. +20.86% in the 10 mg group, although statistically insignificant at P=0.127) and relative percentage necrotic core component (significantly at +1.68% vs. +7.57% in the 10 mg group, P=0.037), as compared to the 10 mg group ( Table 3) . The paradoxical increase in relative percentage necrotic core component in the 40 mg group (while the absolute volume had actually decreased) was just "relative", due to the reduction of the absolute fibrous volume, which constituted >60% of the total percentage plaque volume imposing an overwhelming effect on the other components, with a summation total percentage of 100% (refer to the pie charts in Figure 3) . Figure 4 shows the significant between-group differences observed in this study. The mean LDL-cholesterol level achieved was below 70 mg/dl at 6 months in both groups, and was lower in the moderate-dose (40 mg) group (1.35±0.33 mmol/L 52.12±12.63 mg/dl vs. 1.77±0.69 mmol/L 68.53±26.80 mg/dl in the 10 mg group, P=0.025). In the between-group differences, there was a significant reduction in the percentage plaque volume in the 40 mg group, in contrast to an increase in the 10 mg group (1.50±3.85% vs. 0.38±4.05% in the 10 mg group, 95% CI 0.39-3.36, P=0.014). Most importantly, there was less expansion observed in the relative percentage necrotic core component in the 40 mg group than the 10 mg group (1.68± 7.57% vs. 4.78±7.82%, 95% CI 0.19-5.99, P=0.037). However, we could not identify any significant correlations between these lowered LDL-cholesterol levels, the percentage plaque volumes and relative percentage necrotic core compositions, presumably due to the small sample size used or other pleiotropic effects of statin treatment, like anti-inflammatory actions not mediating through LDL-cholesterol lowering. [13] [14] [15] Similarly, serum high-sensitive C-reactive protein (hs-CRP) levels also showed no significant differences or correlations with other parameters (refer to the Appendix). 
Discussion
The 40 mg atorvastatin dose used in this study would likely be considered a "moderate" dose in reported studies that used "intensive statin therapy" in which 80 mg of atorvastatin was used. However, we considered 40 mg clinically more realistic and safer, and already representing a high dose in the Asian population; the efficacy was reflected by the significant drop in LDL-cholesterol levels ( Table 1) . Volumetric IVUS has long been used in statin trials to evaluate plaque volume and plaque regression. 4-9 For plaque tissue characterization, VH-IVUS 11 or integrated backscatter (IB)-IVUS 16 are far more important, and studies based on both of these technologies have been reported. The former technology FU, follow-up; VH-IVUS, virtual histology intravascular ultrasound. *P-value of paired t-test of change from baseline to 6-month within-group comparison (each of the 10 mg or 40 mg group). † P-value of independent t-test and 95% confidence interval of change in 6 months between-group (10 mg vs. 40 mg) comparison. ‡ P-value of independent t-test between-group (10 mg vs. 40 mg) comparison of absolute fibro-fatty volume at 6 months=0.024. § P-value of independent t-test between-group (10 mg vs. 40 mg) comparison of relative % fibro-fatty component at 6 months=0.029. Figure 4 . Individual changes in plasma LDL-cholesterol level, percentage plaque volume (%) and relative percentage VH-IVUS necrotic core component (%). Significant differences were present between the 2 groups. In statin-naive patients, a higher dose of atorvastatin resulted in a reduction in percentage plaque volume, in concordance with previous reports using intensive statin doses. The finding of more limitation in relative percentage necrotic core expansion with a higher statin dose appeared to support our hypothesis that statin might have dose-dependent effects on VH-IVUS plaque composition. LDL, low-density lipoprotein; VH-IVUS, virtual histology intravascular ultrasound. LEE SWL et al.
was adopted in this study. The essential findings of the present study are as follows. It demonstrated in statin-naive patients with stable coronary artery disease requiring PCI, a mere 6 months of atorvastatin therapy did not, irrespective to the dose used, just improve the lipid level, but also led to the regression of coronary plaque volume and intensive modulation of various plaque compositions in those non-culprit lesions (Table 3) . Importantly, with a 40 mg dose, a significant plaque volume regression of -1.5% was achieved. Also, at this dose, there was a significant reduction in fibrous tissue content, slowing down of progression of dense-calcium, and the stopping of expansion of necrotic core component; all of these did not appear to alter to the same extent as treatment with 10 mg (Figure 3) . The most important observation in this study was, at a higher 40 mg dose, atorvastatin achieved "more limitation of necrotic core expansion" in terms of both the absolute volumes (although not statistically significant at -4.88% vs. +20.86% in the 10 mg group, P=0.127) and the relative percentage necrotic core component (significantly at P=0.037). To the best of our knowledge, a significant limitation of necrotic core expansion (in terms of relative percentage necrotic core component here) was for the first time shown to be statin-dose dependent, with more limitation at a higher dose of 40 mg (Figure 4) . Better clinical outcomes also appeared to follow.
Possible Statin-Specific Effects on Plaque Compositions
Extremely variable results have been published on the effects of different drugs on plaque composition using VH-IVUS. Ogasawara et al reported an increased fibrous, no change in fibro-fatty, mild decrease in dense calcium, and a significant reduction in necrotic core component in Type II diabetic patients after 6 months treatment with pioglitazone. 17 In the IBIS 2 Trial, Serruys et al reported that darapladib stopped necrotic core expansion, which was not observed in the control group. 18 For statin trials, in a very recent study reported by Nozue et al comparing 8 months pitavastatin (4 mg daily) to pravastatin (20 mg daily) treatment, pitavastatin induced a reduction in fibrous and fibro-fatty tissue but an increase in necrotic core while pravastatin showed no effects on fibrous tissue and the necrotic core but a decrease in fibro-fatty tissue. 19 In another short study (2-3 weeks statin therapy after ACS) also comparing pitavastatin 2 mg to atorvastatin 10 mg, Toi et al reported a significant drop in the fibro-fatty volume index in the former group, with no effects in the latter. 20 Hong et al compared simvastatin 20 mg vs. rosuvastatin 10 mg over 1 year, and reported an overall increase in fibro-fatty volume and a decrease in necrotic core component in all patients; however, while these changes were significant in the rosuvastatin group, these were not significant in the simvastatin group. 21 Nasu et al reported a 1 year treatment with fluvastatin 60 mg, which significantly reduced fibro-fatty tissue but fibrous tissue expansion continued, with little effects on dense calcium and necrotic core. 22 Using IB-IVUS, Kawasaki et al showed after 6 months of pravastatin 20 mg vs. atorvastatin 20 mg treatment that both statins increased the fibrous volume but reduced the lipid component. 23 In another very recently published report (the Heaven Study by Kovarnik et al), a 12-month dual lipid-lowering therapy (atorvastatin 80 mg and ezetimibe 10 mg) was compared to atorvastatin 10 mg alone. 24 Plaque regression was achieved in the dual therapy group only, yet in both groups treated with atorvastatin, a continuous shift (reduction) of fibrous and fibrofatty component towards (increase) dense calcium and necrotic core was observed. Comparing this recent report with our present study, which also used atorvastatin, both studies showed almost identical trends of plaque composition changes (a closely matched observation of continuous shift in plaque compositions from fibrous and fibro-fatty tissue to dense calcium and necrotic core). The only major difference between these 2 studies was in our "statin-naive" patients; a 40 mg dose of atorvastatin (a high dose already in the Asian population) appeared to have a more profound effect in confining the atherosclerotic progression, namely more limitation of the expansion of dense calcium and necrotic core component (effects observed in the 10 mg group were much less; refer to the bar charts in Figure 3 ) while in the Heaven Study, plaque compositions did not seem to alter much even at 80 mg of atorvastatin. From all of these studies, it appears that there is a lot of variation in plaque composition outcomes with different statins; there is no consensus on the effects of statin treatment on coronary artery plaque composition, and such effects could be "statin-specific", varying among different statins. This important observation warrants further confirmation by intensive studies that have better matched baseline demographics, baseline plaque volume and VH-compositions, equivalent doses of statins, and long enough follow-up periods.
None of the above studies looked into the simultaneous effects of varying doses of the same statin on VH-IVUS composition. The only other study reporting the use of varying atorvastatin doses (5 mg vs. 20 mg) was conducted by Ishii et al, who showed a reduction in F-18 fluorodeoxyglucose uptake in atherosclerotic plaques by positron emission tomography (a marker of plaque inflammation process) and a significantly reduced serum malondialdehyde-modified LDL-cholesterol level, reflecting a slowing down of arterial inflammation and possibly necrotic core expansion; but these were only seen in the 20 mg group, with no effects in the 5 mg group. 25 Such dose-dependent effects on plaque inflammation strengthened our postulation that statin effects on VH-IVUS composition could also be "statin-dose dependent".
Potential Inaccuracy of VH-IVUS as Compared to IB-IVUS
VH-IVUS was used in this study. The high amount of variation in VH-IVUS results among different studies suggests that, apart from possible "statin-specific" effects as discussed above, there could be other factors operating, including some inherent inaccuracy of the VH technology, even though it has been previously validated to be comparable to histopathology. 12 Initial quantification of plaque component with VH-IVUS has only been tested in rabbit models 26 and the recent report on its poor correlation with necrotic core in porcine model has raised worrying concerns. 27 IB-IVUS has also been used in several studies 23,28 and appeared to show better accuracy in tissue characterization in coronary plaques than VH-IVUS, as reported by Okubo et al. 29 IB-IVUS is especially effective in assessing plaque lipid content, and has been used by Amano et al to show that the lowered serum omega-3 polyunsaturated fatty acid level could be associated with more ACS and higher lipid-rich plaques. 30 However, IB-IVUS might also have a downside, namely it might be more prone to over-estimate the lipid pool in larger vessels, presumably due to higher signal attenuation in bigger vessel walls being falsely interpreted as lipid component, as suggested by Ko et al and Chinali et al. 31 , 32 It appears that with current technology, both VH-IVUS and IB-IVUS have their limitations on necrotic core and fibro-lipid assessment, respectively. Caution must therefore be exercised when drawing conclusions from different studies using different IVUS approaches.
The observed trend of changes in plaque composition in this study was quite similar to that of the Heaven Study. 24 On closer Varying Statin Doses on VH-IVUS Composition examination of the individual VH-IVUS components in our study (Figure 3) , the fibrous component was significantly reduced by statin treatment in either group but showed no statistically significant difference between the 2 groups. The changes in fibro-fatty component were too elusive to allow for any conclusion to be drawn from this small sample. In most published series with statin intervention, the fibro-fatty component tends to decrease. 19,20,22 Such change was observed in the 10 mg group only in our study. Coronary calcification is an unequivocal sign of inflammation and will progress over time. Except in one study that reported a reduction in calcification progression after treatment with cerivastatin, 33 no effects were recorded by IVUS or electron-beam computed tomography in other studies, even with intensive statins doses. 34, 35 Similarly in this study, the dense calcium component in either group showed little response to statin treatment, with continuous progression in both groups. Lastly, for the necrotic core component, it is generally regarded as an inflammatory, unstable component closely related to plaque instability and vulnerability, especially in the context of large lipid core and thin cap fibroatheroma, which could rupture and cause acute MI and sudden death. 10, 36 The general consensus is necrotic core reduction with drug treatment is important and such a reduction might be associated with better outcomes. 17,18,21-23 Results in this study showed that limitation of necrotic core expansion only occurred with 40 mg of atorvastatin in statin-naive patients, with better clinical outcomes.
All parties in the study were blinded to the statin doses, leading to the incidental difference between the baseline plaque volumes, which were adjusted statistically. Similarly, all MACE recorded was only identified to be in the 10 mg group after the unblinding process at the end of the study (Table 1) , even though most of the events were just driven by angiographic restenosis without clinical ischemia. This observation is in keeping with other reports that used statin therapy, in which only minute plaque regression not discernible by coronary angiogram will be sufficient to generate better outcomes and significant reduction in acute cardiac events, 8,37-39 even though the mediating mechanism, whether by pure lipid-lowering effects or by other pleiotropic effects, remains uncertain with big controversies between different studies. 15, 40 As shown in Figure 4 , a higher dose (40 mg) of atorvastatin resulted in a mere 2% (P=0.014) more reduction in the percentage plaque volume and importantly a 3% (P=0.037) more reduction in the relative percentage necrotic core component; better outcomes were already observed in this small sample. However, we could not identify any direct correlations between the LDL-cholesterol levels, the hs-CRP levels, and the percentage plaque volumes and necrotic core volumes.
Study Limitations
There were a few limitations in this study. First, for ethical reasons a placebo group was eliminated at the design beginning of this study. As a result, some of the interval differences observed between the 2 doses had to be inferred from existing reported data with placebo groups. Second, the small sample size in this study was not powered to show statistically significant between-group differences in all parameters. Larger sample sizes, longer treatment durations and higher dose(s) of statin might help to establish the various correlations more clearly. Third, only statin-naive and stable patients were enrolled. These results might not be applicable to other patients, particularly those with ACS. Fourth, as discussed, the effects on plaque components could be "statin-specific". Thus, cross interpretation of our results to other statin studies requires some adjudication. Lastly, limitations imposed by the potential inaccuracy of VH-IVUS in assessing plaque composition as compared to IB-IVUS must be emphasized; future advancement in IVUS technology with more vigorous validation might mitigate this concern.
Conclusions
In statin-naive patients, 6 months treatment with atorvastatin (10 mg and 40 mg) showed substantial modifications in both plaque volume and VH-IVUS plaque compositions. A higher dose (40 mg) of atorvastatin resulted in a reduction in percentage plaque volume (similar to previous reports using intensive statin therapies), and more limitation in relative percentage necrotic core expansion, possibly supporting our hypothesis that statin effects on VH-IVUS plaque composition could be dose-dependent. Large scale studies are required to confirm these findings.
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